Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

NCT03458260 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Aggressive Non-Hodgkin Lymphoma

Interventions

DRUG: Pixantrone
OTHER: Ifosfamide
OTHER: Etoposide
OTHER: Rituximab
PROCEDURE: Transplant

Sponsor

The Lymphoma Academic Research Organisation